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ABSTRACT
Introduction: We aimed to assess if ranolazine
would improve angina symptoms among
patients with documented myocardial
ischemia.
Methods: Eligible subjects had chronic
stable angina and at least one coronary
stenosis with fractional flow reserve (FFR)
B0.80 or at least one chronic total occlusion
(CTO) without attempted revascularization.
Subjects were randomized to oral ranolazine
500 mg twice daily for 1 week, then ranolazine
1000 mg twice daily for 15 weeks versus
matching placebo. The primary end point was
change in angina at 16 weeks as assessed by the
Seattle Angina Questionnaire (SAQ).
Results: Between September 2014 and January
2016, 25 subjects were randomized to
ranolazine versus 25 to placebo. The most
common reason for eligibility was CTO (72%),
while the remainder had myocardial ischemia
documented by low FFR. The mean FFR was
0.57 ± 0.12. Sixty-eight percent of subjects were
on two or more anti-angina medications at
baseline. Study medication was discontinued in
32% (eight of 25) of the ranolazine group versus
36% (nine of 25) of the placebo group. By
intention-to-treat, 46 subjects had baseline and
follow-up SAQ data completed. Ranolazine was
not associated with an improvement in angina
compared with placebo at 16 weeks. The results
were similar among 33 subjects that completed
study medication. The incidence of
ischemia-driven hospitalization or
catheterization was 12% (three of 25) of the
ranolazine group versus 20% (five of 25) in the
placebo group (p[0.05).
Conclusions: In subjects with chronic
stable angina and documented myocardial
ischemia, ranolazine did not improve angina
symptoms at 16 weeks.
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INTRODUCTION
Revascularization by percutaneous coronary
intervention (PCI) or coronary artery bypass
grafting (CABG) is feasible for the majority of
patients with symptomatic ischemic heart
disease, with resolution of their symptoms.
However, many of these patients continue to
have angina symptoms due to residual
ischemia, which can result in repeat
revascularizations and adverse cardiovascular
events [1, 2]. Ranolazine is an anti-ischemia/
anti-angina medication that inhibits the late
sodium current but does not affect the heart
rate or blood pressure [3]. Ranolazine was
associated with a reduction in recurrent
ischemia among patients with acute coronary
syndrome and history of angina [4]. In the
Ranolazine for Incomplete Vessel
Revascularization Post-Percutaneous Coronary
Intervention (RIVER-PCI) multicenter
randomized trial, ranolazine failed to reduce
ischemia-driven hospitalization or
ischemia-driven revascularization in chronic
angina patients with incomplete
revascularization [5]. However, incomplete
revascularization was assessed
angiographically, which is known to only
modestly correlate with underlying myocardial
ischemia [6, 7].
Therefore, we aimed to assess whether
ranolazine would improve angina symptoms
and subjective well-being among patients with
documented myocardial ischemia, defined by
either low fractional flow reserve (FFR) or
presence of a chronic total occlusion (CTO),
and who did not undergo revascularization.
METHODS
Study Design and Selection Criteria
This was a randomized single-center trial that
enrolled subjects at least 18 years of age who
were referred for catheterization for evaluation
of angina, fatigue, or shortness of breath. This
investigator initiated study was sponsored by
Gilead Sciences. In addition to symptoms
compatible with chronic stable angina, we
required the following: (1) at least one
borderline coronary stenosis with documented
myocardial ischemia by FFR (B0.8) or at least
one CTO, and (2) no attempted
revascularization of the ischemic artery. CTO
was defined as an occlusion in a C2 mm
epicardial coronary artery in which distal flow
was provided by antegrade or retrograde
collaterals. An occlusion which was supplied
by a patent bypass graft was not considered a
CTO. The assumed FFR value of a CTO was 0.5
[8]. The decision not to revascularize an
ischemic lesion was left to individual operator
discretion, but included the following reasons:
patient preference for initial medical therapy,
lesion characteristics that increased the risk for
restenosis (diffuse disease in a small vessel), or
characteristics that increased the risk for
procedural complication (severe calcification,
excessive angulation/tortuosity, or inability to
protect a bifurcation lesion). The following
patients were excluded; coronary
revascularization within the index procedure
or planned in the next month, acute coronary
syndrome or cardiogenic shock, use of strong
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inhibitors of CYP3A, use of inducers of CYP3A,
liver cirrhosis, severe renal insufficiency
(creatinine clearance \30 ml/min/1.73 m2), or
baseline corrected QT interval[500 ms.
Randomization
Eligible subjects were randomly assigned to
receive either oral ranolazine 500 mg twice
daily for 1 week, then ranolazine 1000 mg
twice daily for 15 weeks vs. matching placebo
(one tablet twice daily for 1 week, then two
tablets twice daily for 15 weeks). Randomization
was performed with Excel 2010 utilizing the
RAND function. A sample size of 50 was
randomized using a simple schema with two
levels representing treatment assignments
without stratification. Block size was set at 10.
Study investigator, patient, and research team
were blinded to treatment assignment. The
treatment assignment code was kept by
research pharmacy.
Endpoints and Statistics
The primary end point was change in angina
from baseline to 16 weeks as assessed by the
Seattle Angina Questionnaire (SAQ) [9].
Secondary endpoints included subjective
well-being, in which subjects were asked, ‘‘in
the last month, how would you rate your
overall feeling of well-being (poor, fair, good,
or excellent) [10].’’ Lastly, the incidence of
ischemia-driven hospitalization or
catheterization was assessed. Baseline
characteristics were described as frequencies
for categorical variables and means, with
standard deviations, for continuous variables.
Student’s t test, and the v2 test were used for the
comparison of the continuous and categorical
variables, respectively. Paired t test was used to
compare the changes within a group. Statistical
significance level was defined as p\0.05. All
statistical analysis was conducted using SAS 9.4
(SAS Institute, Inc., Cary, NC, USA). We
conducted power analysis based on the SAQ
results measured in a previous study [11]. We
hypothesized that patients at baseline would
have a mean ± SD of 53 ± 23 for physical
limitation, 64 ± 28 for angina frequency,
53 ± 28 for angina stability, 79 ± 19 for
treatment satisfaction, and 50 ± 22 for disease
perception [2]. Assuming a 20% change after
follow up 16 weeks, it was estimated that 14-53
patients in each domain would give an 80% of
power to detect a statistically significant
difference between baseline and follow up
(a = 0.05).
Safety and Ethics
Institutional review board approval was
obtained from the University of Florida. The
study was registered at ClinicalTrials.gov
(NCT02265796). An independent data safety
monitor periodically reviewed adverse events to
evaluate if there were any potential safety
issues. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from all patients for being included in the
study.
RESULTS
Between September 2014 and January 2016, 25
subjects were randomized to ranolazine versus
25 to placebo. Follow-up SAQ was not obtained
in four subjects. This was due to one death, and
two study withdrawals in the ranolazine group
and one study withdrawal in the placebo group.
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The most common reason for anatomic
eligibility was chronic total occlusion that was
present in 72%, while the remainder had
myocardial ischemia documented by FFR
(mean FFR value was 0.57 ± 0.12). The mean
age was 67 years ± 9 years, mean left ventricular
ejection fraction was 53 ± 11%, and mean left
ventricular end diastolic pressure was 12
± 5 mmHg. Sixty-eight percent of subjects
were on two or more anti-angina therapies at
baseline (80% on a beta-blocker, 60% on a
long-acting nitrate, and 35% on a calcium
channel antagonist). Additional baseline
characteristics are provided in Table 1.
Discontinuation of study medication
occurred in 32% (eight of 25) of the
ranolazine group at a mean of 55 ± 46 days
(median, 46 days) versus 36% (nine of 25) of the
placebo group at a mean of 31 ± 27 days
(median, 31 days) (p[0.05). Dizziness or
impaired memory was reported in 20% (five of
25) of the ranolazine group versus 12% (three of
25) in the placebo group (p[0.05). Other
reasons for drug discontinuation in the
ranolazine arm included: tiredness (one
patient), started on another QT prolonging
medication (i.e., primidone), and one patient
stopped the medication for no clear reason.
By intention-to-treat, 46 subjects had
baseline and follow-up SAQ data completed at
16 weeks. Three out of five SAQ domains
improved from baseline to follow-up in both
groups (Angina Stability, Angina Frequency,
and Quality of Life); however, there was no
difference between the treatment and placebo
groups (Table 2). There was no within-group
change in Physical Limitation, or Treatment
Satisfaction (Table 2). There was also no change
in subjective well-being over the follow-up
period (Table 3). The results were similar
among 33 subjects that completed study
medication.
At 16 weeks, the incidence of
ischemia-driven hospitalization or
catheterization was three out of 25 in the
ranolazine group versus five out of 25 in the
placebo group (p[0.05).
DISCUSSION
Among patients with documented myocardial
ischemia (mean FFR = 0.57) and no attempted
revascularization, ranolazine failed to improve
angina symptoms or subjective well-being
compared with placebo. Findings were the
same by intention-to-treat analysis and also
among the cohort that completed their
treatment assignment. As a secondary
outcome, incidence of ischemia-driven
hospitalization or catheterization was similar
between treatment groups. Discontinuation of
study medication was high, but similar
between groups and there was no appreciable
difference in adverse events between treatment
groups.
Lack of benefit could be due to good
background medical therapy (68% on two or






Past medical history (%)
Hypertension 100 100 [0.99
Hyperlipidemia 64 67 0.83
Diabetes mellitus 55 63 0.58
On insulin 18 29 0.50
h/o PCI 77 54 0.10
h/o CABG 32 25 0.61
CABG coronary artery bypass grafting, h/o history of, PCI
percutaneous coronary intervention
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more anti-angina therapies at baseline) versus
relative ineffectiveness of ranolazine as an
anti-angina agent [12]. There was also a strong
placebo effect. For example, subjects
randomized to placebo experienced a six-unit
improvement in angina stability, a 15-unit
improvement in angina frequency, and an
18-unit improvement in quality of life.
Inadequate power also remains a possible
explanation for the lack of association
between ranolazine and angina measures.
While anti-angina therapy is an important
treatment strategy among patients with
ischemic heart disease [13], PCI has been
shown to provide greater angina relief
compared with optimal medical therapy [14].











Baseline 48 ± 25 50 ± 20
16 weeks 40 ± 19 60 ± 24
Change* -7 ± 27 (p = 0.31) 6 ± 20 (p = 0.22) p = 0.12 p = 0.13
Angina stability
Baseline 39 ± 28 37 ± 28
16 weeks 58 ± 26 55 ± 27
Change* 19 ± 36 (p = 0.025) 18 ± 32
(p = 0.0093)
p = 0.94 p = 0.78
Angina frequency
Baseline 65 ± 24 64 ± 23
16 weeks 81 ± 23 80 ± 24
Change* 16 ± 36 (p = 0.055) 15 ± 27
(p = 0.0095)
p = 0.98 p = 0.66
Treatment satisfaction
Baseline 80 ± 19 85 ± 18
16 weeks 77 ± 26 82 ± 22
Change* -4 ± 26 (p = 0.52) -3 ± 26 (p = 0.64) p = 0.89 p = 0.70
Quality of life
Baseline 37 ± 24 45 ± 27
16 weeks 56 ± 29 63 ± 28
Change* 21 ± 32 (p = 0.0067) 18 ± 31
(p = 0.0083)
p = 0.76 p = 0.74
*Within-group difference
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At the time this studywas designed, RIVER-PCI
was actively enrolling.Ourfindingswere similar to
the overall negative findings of the later reported
RIVER-PCI trial [5]. In addition, among 864
patients enrolled with a chronic total occlusion
in the RIVER-PCI trial, ischemia-driven
revascularization or ischemia-driven
hospitalization occurred in 27% of the ranolazine
groupversus30%of theplacebogroup (HR= 0.95,
95% CI 0.74–1.22, Pinteraction = 0.91) [5]. This
group is most similar to the characteristics of our
study participants. There was also no
improvement in angina burden from ranolazine
versus placebo in the overall RIVER-PCI trial [15].
This study was intended to be a pilot study to
investigate for any potential benefit in this patient
population, and in sodoing to estimate the sample
size needed for a definitive study. However, given
the lack of benefit in the present study, a larger
study is not planned.
This study has some limitations. The primary
outcome was relatively subjective; however,
SAQ has been previously validated and is
widely used in ischemic heart disease studies.
In addition, a large proportion of patients
discontinued the study medication; however,
the rate of discontinuation was the same
between study drug and placebo. The small
sample size might have decreased to study
power to detect statistically significant
differences between both groups. Additionally,
there was no difference in the intention-to-treat
analysis versus the on-treatment analysis.
CONCLUSIONS
In conclusion, among subjects with chronic
stable angina and documented myocardial
ischemia, ranolazine did not improve the
frequency of angina or subjective well-being at
16 weeks.
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16 weeks 50 42
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